« Return to News | Drug Sponsors | R&D Trends

Boehringer Ingelheim forms partnerships

Wednesday, March 16, 2011 12:53 PM

Boehringer Ingelheim has entered into an antibody deal with fellow German firm MorphoSys and signed a diabetes technology pact with Depomed, according to Pharma Times.

The MorphoSys agreement covers the process development and manufacturing of additional clinical material for MOR208, a monoclonal anti-CD19 antibody for the treatment of chronic lymphocytic leukaemia and potentially other B-cell malignancies. It is currently being evaluated in a phase I trial in the U.S. by MorphoSys's partner Xencor.

Simon Sturge, head of the biopharmaceuticals division at Boehringer, said the combination of MorphoSys' track record in the discovery and clinical side of antibody-based therapeutics "and our proven competence in technical development and manufacturing will be an optimal fit."

Boehringer has obtained worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to develop certain fixed-dose combination products which include extended-release metformin and Boehringer compounds for type II diabetes.

Boehringer is paying a $12.5 million license fee, $10 million upfront and an additional $2.5 million payable upon delivery of experimental batches of prototype formulations. Depomed is also eligible to receive additional milestone payments and royalties.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.